First Coast Mohs has been acquired by AQUA Dermatology
Dermatology and skin cancer specialist First Coast Mohs has partnered with AQUA Dermatology.
First Coast Mohs offers Mohs surgery, surgical and medical dermatology, dermatopathology, cosmetic and laser treatments, electrolysis and other aesthetic services from four state-of-the-art facilities in metro Jacksonville, Florida. The practice features seven clinicians, including two Mohs surgeons, two board certified dermatologists and three Advanced Practice Providers. First Coast Mohs was founded in 2002 by Dr. Scott Warren, who will continue to lead the practice following the transaction.
AQUA Dermatology, backed by Gryphon Investors and GTCR, is the largest dermatology practice in the southeastern United States with over 110 locations and 250 providers. For more than 25 years, the company has treated patients of all ages suffering from skin diseases, acne, sun damage, skin cancer and vein health issues, as well as those seeking cosmetic and plastic surgery. With First Coast Mohs, AQUA Dermatology now has 78 locations in Florida.
Oaklins Heritage in Jacksonville served as the intermediary and exclusive financial advisor to the seller in this transaction.



Dr. Scott Warren
Owner, First Coast Mohs
Talk to the deal team
Related deals
The Providence Projects has been acquired by UKAT Group
Celebrity-success rehabilitation center, The Providence Projects, has joined The UK Addiction Treatment (UKAT) Group, backed by Sullivan Street Equity Partners.
Learn moreNorthlane Capital Partners has sold Empower Community Care to NexPhase Capital
Northlane Capital Partners has successfully completed the sale of Empower Community Care to NexPhase Capital.
Learn moreSt. Claraspital AG has been acquired by University Hospital Basel
University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care. The completion of the transaction is subject to clearance by the Swiss Competition Commission (COMCO).
Learn more